NCT01156636View on ClinicalTrials.gov

Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

December 31, 2009

Conditions
Pulmonary HypertensionDiastolic Heart Failure
Interventions
DRUG

Sildenafil

50 mg 3 times/day for 1 year

DRUG

Placebo

All Listed Sponsors
lead

University of Milan

OTHER

NCT01156636 - Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure | Biotech Hunter | Biotech Hunter